Table III.

Functional limitations with the Short Form 36 in patients with rheumatoid arthritis and ankylosing spondylitis evaluated at different study sites.

Reference	Year	Patients no.	Age yrs*	Male %	Disease Duration, yrs*	SF-36 Physical Function
RA Ruta et al.100	1998	233	56 ± 14	19	13 ± 13	31 ± 29
Fransen et al.59	2002	803	59 ± 13	29	≠7 (2, 14)†	55 (33.3, 80)†
Dadoniene et al.61	2003	201◊	55.9 ± 10.0	17	11.9 ± 9.5	35.2 ± 25.2
Wolfe et al.65	2004	14038	–	–	–	47.1 ± 28.4
Escalante et al.64	2004	776	57†	30	8†	35.6 ± 27.9
Koh et al.80	2006	401	57 ± 10.9	14	11 ± 13	64.5 ± 28.1***
Rupp et al.101	2006	882	59.8 ± 14.8	28	8.9 ± 9.8	49.0 ± 27.2
Soderlin et al.89	2007	594	64	27	17	49
Uhlig et al.40	2008	914	58.7 ± 13.4	21	13.6 ± 10.5	54.5
Alishiri et al.102	2008	411	46.8 ± 12	13	6.3 ± 5.7	50.9 ± 26.4
AS Ward103	1999	175	51.1 ± 14.0	68	23.7 ± 14.3	66 ± 27
Dagfinrud et al.104	2004	314	43.7 ± 12.3	63	13.3 ± 11.3	71 ± 23
Turan et al.105	2007	46	39.2 ± 11.5	80	13.9 ± 10.4	62.4 ± 25.9
Zhu et al.12	2008	145	40 ± 11.1	79	10 ± 7.9	65
Vesovic-Potic et al.106	2009	74	48.5 ± 10.3	78	15.2 ± 8.8	64.4 ± 16.7

SF-36 PF: Short Form 36 Physical Functioning subscale

^*All values are mean ± standard deviation, unless otherwise noted

^†Median with interquartile range

^◊Vilnius cohort

^***Chinese adaptation of the SF-36.